LRP6-Targeted mRNA Vaccine Offers New Hope for Triple-Negative Breast Cancer Treatment
TNBC, Crisis of Therapeutic Absence
Triple-negative breast cancer (TNBC) exhibits high recurrence rates and strong resistance to existing therapies, resulting in low patient survival. Overexpression of the protein LRP6, which promotes tumor growth and metastasis, has been a major concern.
AI-Designed mRNA Vaccine Targeting LRP6
The research team employed bioinformatics and molecular modeling to design an mRNA vaccine directed against LRP6. The final construct comprises 431 amino acids, a molecular weight of 47.5 kDa, a theoretical pI of 5.11, and an instability index of 38.3, indicating stability, and it demonstrates a global population coverage of 99.04%.
Robust Immune Response and Worldwide Applicability
Molecular docking revealed high binding affinities to immune receptors HLA‑A0201 (‑812.0), HLA‑A0301 (‑707.1), HLA‑DRB1*0101 (‑955.7), and TLR9 (‑1339.5). Immune simulation predicted high concentrations of IgG1 antibodies, memory B‑cell counts exceeding 200, CD4⁺ T‑cell numbers above 3000, and strong IFN‑γ responses. Codon optimization achieved a CAI of 0.94 and a GC content of 58.37%, supporting efficient expression in human cells.
Future Significance and Outlook
If this vaccine progresses to clinical trials, it could provide a personalized immunotherapeutic option for TNBC patients, extending survival. Moreover, the mRNA‑based cancer‑vaccine platform may be expanded to other tumor types.
BACKGROUND: Triple-negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options. TNBC exhibits increased levels of LRP6 expression, which is linked to tumor-related features such as growth, metastasis, poor prognosis, resistance to chemotherapy, and invasion. Therefore, LRP6 offers a promising option for therapeutic intervention in breast cancer. AIMS: This research aims to use in silico and bioinformatics techniques to develop an mRNA vaccine that specifically targets the LRP6 antigen. METHODS AND RESULTS: The final vaccine construct comprised 431 amino acids, with a molecular weight of 47.5 kDa, theoretical pI of 5.11, and an instability index of 38.3 indicating stability. Population coverage analysis showed broad global coverage of 99.04%. Molecular docking revealed strong binding affinities to immune receptors, including HLA-A0201 (-812.0), HLA-A0301 (-707.1), HLA-DRB1*0101 (-955.7), and TLR9 (-1339.5). Immune simulation predicted high titers of IgG1 antibodies, sustained memory B cell populations (> 200 by Day 365), elevated CD4+ T cells (> 3000), and robust IFN-γ responses. Codon optimization yielded a high CAI value of 0.94 and GC content of 58.37%, supporting efficient expression in human systems. CONCLUSION: Collectively, these results suggest that the designed LRP6-targeted mRNA vaccine could induce durable humoral and cellular immunity against TNBC and warrants further experimental validation.
This study addresses the low treatment success rates in triple‑negative breast cancer patients, for whom therapeutic options have been virtually nonexistent. Implementation of a personalized mRNA vaccine in clinical practice could enable patients to live longer and maintain their daily activities.